


Cefozopran

Cat. No.:	HY-B0771
CAS No.:	113359-04-9
Molecular Formula:	C ₁₉ H ₁₇ N ₉ O ₅ S ₂
Molecular Weight:	515.53
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cefozopran (SCE-2787) is a semi-synthetic, parenteral, fourth-generation cephalosporin. Cefozopran, an antibiotic, has a broad spectrum of antibacterial activity, inhibiting most of the gram-negative and gram-positive organisms ^{[1][2]} .
IC₅₀ & Target	β-lactam
In Vitro	Cefozopran (SCE-2787) is a fourth-generation cephalosporin that has good activity against gram-positive organisms including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci; and against gram-negative organisms including hemophilus influenza. Moreover, cefozopran has comparatively good activity against enterococci and <i>P. aeruginosa</i> , which are refractory to other cephalosporins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cefozopran (SCE-2787) (5-80 mg/kg; s.c.; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by <i>Kiebsiella pneumoniae</i> DT-S. In the model of chronic respiratory tract infection caused by <i>K. pneumoniae</i> 27, Cefozopran (20-80 mg/kg; s.c.; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sato T, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. *Pediatr Blood Cancer*. 2008;51(6):774-777.

[2]. Iizawa Y, et al. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice. *Antimicrob Agents Chemother*. 1993;37(1):100-105.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA